Apricus Biosciences, Inc (APRI)
(Delayed Data from NSDQ)
$0.22 USD
0.00 (0.00%)
Updated Jan 23, 2019 03:57 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Seelos Therapeutics, Inc. [APRI]
Reports for Purchase
Showing records 1 - 20 ( 96 total )
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Terminating coverage due to resource reallocation.
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for APRI
Provider: ValuEngine, Inc
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
2017 Financial Results Reported; FDA Meeting Expected Next Month; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros Complete Response Letter Received; Downgrade to Neutral with $1 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros PDUFA Date One Month Away; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
3Q17 Results Reported; Vitaros NDA Review on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros PDUFA Date Set for February 17, 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros NDA Resubmitted; Potential PDUFA in 1Q18; Reiterate Buy and Increasing Price Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros NDA to Be Resubmitted in the Current Quarter; 2Q17 Financial Results; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros NDA to Be Resubmitted in the Current Quarter; 2Q17 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros NDA Resubmission On Track in 3Q17; 1Q17 Financial Results; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Vitaros NDA Resubmission On Track in 3Q17; 1Q17 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Restoring Vim and Vigor With Vitaros; Initiating Coverage at Buy and $4 Price Target
Provider: Rodman & Renshaw, Co.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Restoring Vim and Vigor With Vitaros; Initiating Coverage at Buy and $4 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
Coverage dropped due to discontinuance of research services.
Provider: Taglich Brothers, Inc.
Analyst: NOBILE J
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
We are dropping coverage of APRI shares to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Company: Seelos Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.